54 related articles for article (PubMed ID: 646859)
1. Tumor membrane lymphocyte stimulation assay in patients with renal cell carcinoma.
Hemstreet GP; Dawson JR; Seigler HF
Cancer Res; 1978 May; 38(5):1447-56. PubMed ID: 646859
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma: tumor membrane lymphocyte stimulation assay.
Hemstreet GP
Natl Cancer Inst Monogr; 1978 Dec; (49):165-8. PubMed ID: 748768
[TBL] [Abstract][Full Text] [Related]
3. The macrophage electrophoretic mobility assay in patients with renal cell carcinoma.
Malkovský M; Bubeník J; Jakoubková J; Suhajová E; Indrová M; Jandlová T; Símová J
Neoplasma; 1981; 28(2):245-51. PubMed ID: 7254439
[TBL] [Abstract][Full Text] [Related]
4. Antigenic determinants in a virus-induced mouse mammary tumor recognized by cell-mediated immune assays.
Lopez PF; Parks WP; Lopez DM
J Natl Cancer Inst; 1984 Mar; 72(3):725-32. PubMed ID: 6199544
[TBL] [Abstract][Full Text] [Related]
5. Immunologic evaluation of human renal cell carcinoma. In vitro studies.
Elhilali MM; Nayak SK
Invest Urol; 1975 Jul; 13(1):60-6. PubMed ID: 49333
[TBL] [Abstract][Full Text] [Related]
6. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
Kim TY; von Eschenbach AC; Filaccio MD; Hayakawa K; Parkinson DR; Balch CM; Itoh K
Cancer Res; 1990 Sep; 50(17):5263-8. PubMed ID: 2143685
[TBL] [Abstract][Full Text] [Related]
7. A rapid assay for stimulation of human lymphocytes by tumor-associated antigens.
Roth JA; Grimm EA; Morton DL
Cancer Res; 1976 Sep; 36(9 pt.1):3001-10. PubMed ID: 975069
[TBL] [Abstract][Full Text] [Related]
8. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
9. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
[TBL] [Abstract][Full Text] [Related]
10. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
12. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
13. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte therapy of renal cell carcinoma.
Dillman RO
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte responses of lung cancer patients to tumor-associated antigen measured by leucine incorporation.
Roth JA; Holmes EC; Boddie AW; Morton DL
J Thorac Cardiovasc Surg; 1975 Oct; 70(4):613-8. PubMed ID: 1177475
[TBL] [Abstract][Full Text] [Related]
16. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
17. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte-mediated cytotoxicity in patients with renal and transitional cell carcinoma receiving BCG.
Lange PH
Natl Cancer Inst Monogr; 1978 Dec; (49):343-5. PubMed ID: 748791
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
